You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Chat on-demand with a health outcomes consultant

Explore the cost of the Ellipta portfolio and contact us to find out how this could impact your local prescribing.

Clinical evidence packs for asthma and COPD medicines can be found below.

Asthma medicines evidence pack

Relvar▼ Ellipta (fluticasone furoate/vilanterol) evidence summary pack

The Relvar Ellipta evidence summary pack, in asthma, provides licensing information, clinical, financial and environmental data to support payers/commissioners and healthcare professionals to make a Relvar Ellipta formulary application and/or decide positioning within a local guideline.

To download a PDF copy of the evidence summary pack, click on the image of the document.

Relvar▼ Ellipta (fluticasone furoate/vilanterol) evidence dossier

The Relvar Ellipta evidence dossier in asthma contains more clinical and graphical information to accompany the evidence summary pack providing support to payers/commissioners and healthcare professionals to make a Relvar Ellipta formulary application and/or decide positioning within a local guideline.

To download a PDF copy of the evidence dossier, click on the image of the document.

COPD medicines evidence packs

Relvar▼ Ellipta (fluticasone furoate/vilanterol) COPD medicines evidence pack

The Relvar Ellipta medicines evidence pack in COPD provides information to support payers and HCPs in making a Relvar Ellipta formulary application.

You can access a printer- friendly version of the pack by clicking on the image.

Incruse▼ Ellipta (umeclidinium bromide) COPD medicines evidence pack

The Incruse Ellipta medicines evidence pack in COPD provides information to support payers and HCPs in making an Incruse Ellipta formulary application.

You can access a printer- friendly version of the pack by clicking on the image.

Anoro▼ Ellipta (umeclidinium/vilanterol) COPD medicines evidence pack

The Anoro Ellipta medicines evidence pack in COPD provides information to support payers and HCPs in making an Anoro Ellipta formulary application.

You can access a printer- friendly version of the pack by clicking on the image.

 

ANORO ELLIPTA and RELVAR ELLIPTA were developed in collaboration with

Innoviva logo

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

Anoro, Incruse, Relvar and Ellipta are registered trademarks of the GlaxoSmithKline group of companies 

T.R. Last updated August 2017. UK/RESP/0486/15(4)